PART I Overview CorMedix Inc. (collectively, with our wholly owned subsidiaries, referred to herein as we, us, our or the Company) is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. Our primary focus has been commercializing DefenCath (taurolidine and heparin), in the U.S., which we launched in 2024 in the hemodialysis setting. The name DefenCath is the U.S. proprietary name approved by the U.S. Food and Dru...
Q2 FY2026 — expected 2026-09-08
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-05 | 2025-12-31 | 0001213900-26-023889 | EDGAR | 66K words |
| 2025-03-25 | 2024-12-31 | 0001013762-25-001852 | EDGAR | — |
| 2024-03-12 | 2023-12-31 | 0001213900-24-021585 | EDGAR | — |
| 2023-03-30 | 2022-12-31 | 0001213900-23-024310 | EDGAR | — |
| 2022-03-29 | 2021-12-31 | 0001213900-22-015852 | EDGAR | — |
| 2021-03-30 | 2020-12-31 | 0001213900-21-018684 | EDGAR | — |
| 2020-03-16 | 2019-12-31 | 0001213900-20-006521 | EDGAR | — |
| 2019-03-14 | 2018-12-31 | 0001654954-19-002741 | EDGAR | — |
| 2018-03-19 | 2017-12-31 | 0001654954-18-002777 | EDGAR | — |
| 2017-03-16 | 2016-12-31 | 0001654954-17-002094 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-12 | 2025-09-30 | 0001213900-25-108777 | EDGAR | 42K words |
| 2025-08-07 | 2025-06-30 | 0001213900-25-072843 | EDGAR | — |
| 2025-05-06 | 2025-03-31 | 0001213900-25-039908 | EDGAR | — |
| 2024-10-30 | 2024-09-30 | 0001213900-24-091961 | EDGAR | — |
| 2024-08-14 | 2024-06-30 | 0001213900-24-068600 | EDGAR | — |
| 2024-05-09 | 2024-03-31 | 0001213900-24-041031 | EDGAR | — |
| 2023-11-14 | 2023-09-30 | 0001213900-23-086981 | EDGAR | — |
| 2023-08-08 | 2023-06-30 | 0001213900-23-064244 | EDGAR | — |
| 2023-05-15 | 2023-03-31 | 0001213900-23-039793 | EDGAR | — |
| 2022-11-10 | 2022-09-30 | 0001213900-22-070834 | EDGAR | — |
| 2022-08-11 | 2022-06-30 | 0001213900-22-046617 | EDGAR | — |
| 2022-05-12 | 2022-03-31 | 0001213900-22-025967 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-06 | 0001213900-26-024777 | EDGAR | 4K words |
| 2026-03-05 | 0001213900-26-023881 | EDGAR | — |
| 2026-01-08 | 0001213900-26-002350 | EDGAR | — |
| 2025-11-12 | 0001213900-25-108716 | EDGAR | — |
| 2025-10-20 | 0001213900-25-100156 | EDGAR | — |
| 2025-09-02 | 0001213900-25-082956 | EDGAR | — |
| 2025-08-12 | 0001213900-25-075010 | EDGAR | — |
| 2025-08-07 | 0001213900-25-072814 | EDGAR | — |
| 2025-06-30 | 0001213900-25-059702 | EDGAR | — |
| 2025-06-25 | 0001213900-25-057451 | EDGAR | — |
383 total filings indexed. 351 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001410098 |
| Ticker | CRMD |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.cormedix.com |
| Listed | 2010-05-13 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report